Alberta Enterprise Corporation invests USD$3 million into energy technology fund

Oct 04, 2022

EDMONTON, AB, Oct. 4, 2022 /CNW/ - Alberta Enterprise announced today that it has invested USD $3 million in PillarFour Capital Fund II to support Alberta energy technology companies focused on reducing carbon intensity and environmental footprint in the oilfield.

"Technology has always been a backbone of Alberta's oil and gas sector and forward-thinking energy technology companies continue to play a key role in advancing the industry along a path of increasingly efficient and responsible operations," commented Kristina Williams, CEO of Alberta Enterprise Corporation. "We've been engaged with the PillarFour team for the last few years. We are impressed by the portfolio they created in their first fund, and are excited to support them as they continue to invest in Alberta's energy innovators."

PillarFour is an investment firm focused on sustainable, energy technology companies. The firm is headquartered in Calgary with an additional office in London, England. The PillarFour investment team leverages decades of operational and financial expertise in energy and technology businesses to support Canadian innovators seeking to scale in Canada, into the US and internationally.

Click here to see more...

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.